key: cord-0909597-ivau2qnh authors: Dortet, L.; Ronat, J.-B.; Vauloup-Fellous, C.; Langendorf, C.; Mendels, D.-A.; Emeraud, C.; Oueslati, S.; Girlich, D.; Chauvin, A.; Afdjei, A.; Bernabeu, S.; Le Pape, S.; Kallala, R.; Rochard, A.; Verstuyft, C.; Fortineau, N.; Roque-Afonso, A.-M.; Naas, T. title: Evaluating ten commercially-available SARS-CoV-2 rapid serological tests using the STARD (Standards for Reporting of Diagnostic Accuracy Studies) method. date: 2020-09-11 journal: nan DOI: 10.1101/2020.09.10.20192260 sha: 84301153b1d226b32607ed38a1cbaec6dee8ef1d doc_id: 909597 cord_uid: ivau2qnh Numerous SARS-CoV-2 rapid serological tests have been developed, but their accuracy has usually been assessed using very few samples, and rigorous comparisons between these tests are scarce. In this study, we evaluated and compared 10 commercially-available SARS-CoV-2 rapid serological tests using the STARD methodology (Standards for Reporting of Diagnostic Accuracy Studies). 250 sera from 159 PCR-confirmed SARS-CoV-2 patients (collected from 0 to 32 days after onset of symptoms) were tested with rapid serological tests. Control sera (N=254) were retrieved from pre-COVID periods from patients with other coronavirus infections (N=11), positive rheumatoid factors (N=3), IgG/IgM hyperglobulinemia (N=9), malaria (n=5), or no documented viral infection (N=226). All samples were tested using rapid lateral flow immunoassays (LFIA) from ten manufacturers. Only four tests achieved [≥]98% specificity, with other tests ranging from 75.7%-99.2%. Sensitivities varied by the day of sample collection, from 31.7%-55.4% (Days 0-9), 65.9%-92.9% (Days 10-14), and 81.0%-95.2% (>14 days) after the onset of symptoms, respectively. Only three tests evaluated met French Health Authorities' thresholds for SARS-CoV-2 serological tests ([≥]90% sensitivity + [≥]98% specificity). Overall, the performances between tests varied greatly, with only a third meeting acceptable specificity and sensitivity thresholds. Knowing the analytical performance of these tests will allow clinicians to use them with more confidence, could help determine the general population's immunological status, and may diagnose some patients with false-negative RT-PCR results. Asymptomatic carriage of SARS-CoV-2 has been estimated in some studies to be as high as 65 86 (1). Others posit that it may be responsible for up to two-thirds of viral propagation (1-4). 66 As the world increasingly acknowledges the challenges this poses to disease containment, 67 reliable testing has become central to monitoring the COVID-19 pandemic, informing health 68 policy, rapidly responding to events as they evolve, and mitigating disease transmission (5, 6) . 69 Yet, RT-PCR tests (Real-time reverse transcription-polymerase chain reaction), the gold 70 standard for SARS-CoV-2 detection, have substantial limitations. PCR requires specialized, 71 expensive laboratory equipment, is often only located in laboratories with biosafety level ≥ 2, 72 and may be affected by sample transport delays of 2-3 days, in which time suspects may further expose other patients and health workers (7-9). For SARS-CoV-2, PCR testing also uses naso-pharyngeal swab samples that can be complex to obtain, pose 75 considerable risk to health care workers with insufficient personal protective equipment 76 (PPE), and produce false-negative results in up to 30 of confirmed COVID-19 patients (10-77 12) . Chest radiography (CXR) and computed tomography (CT) scans are currently used to 78 overcome PCR tests' lack of sensitivity but also require expensive equipment (11, 13). These 79 challenges limit current molecular and imaging approaches' ability to be scaled up in 80 epidemic settings where rapid, reliable, and easy population screening is needed. 81 Thus, serological confirmation of COVID-19 antibodies could provide an important 82 complementary tool to PCR testing by identifying previously exposed individuals (8, 12) . 83 SARS-CoV-2 seroconversion occurs 7-14 days after the onset of symptoms (8, (14) (15) (16) . A few 84 classic ELISA tests (enzyme-linked immunosorbent assays) are currently available, but 85 considerable effort has been made by manufacturers to offer even earlier rapid diagnostic tests 86 (RDTs) (17). According to the Foundation for Innovative New Diagnostics (FIND), 177 87 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 To assess specificity, an additional 254 sera collected prior to December 2019 were selected, 113 and which had previously been tested positive for a separate agent or pathology that could 114 potentially interfere with SARS-CoV-2 testing results, either other coronavirus (n=11), other 115 viral infections (n= 129), a rheumatoid factor (n=3), hyperglobulinemia IgG (n=6) and IgM 116 (n=3), malaria (n=5), or a Treponema pallidum hemagglutination assay (TPHA) (n=97) (Fig. 117 1B). 118 Each RDT was evaluated on the same collection of sera. The minimum sample size was 119 calculated assuming an expected sensitivity of 90 (with 5 accuracy) and a specificity of 98 120 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 Ab Test (Innovita Biological Technology CO, Qian'an, China), (RDT 7) 2019-nCoV 138 IgG/IgM (Biolidics, Mapex, Singapore), (RDT 8) COVID-19-CHECK-1 (Veda.Lab, Alençon, 139 France), (RDT 9) Finecare SARS-CoV2 Antibody test (Guangzhou Wondfo biotech, 140 Guangzhou, China) and (RDT 10) Wondfo SARS-CoV2 Antibody test (Guangzhou Wondfo 141 biotech, Guangzhou, China). Characteristics of these RDTs are summarized in Table S1 . 142 Tests were performed at room temperature by trained laboratory technicians. All tests 143 followed the manufacturers' instructions, strict biosecurity measures, and good 144 microbiological practices and procedures [8] . 145 The intensity of the reaction line was recorded in 3 gradations: No signal (0), very weak but 146 definitively positive (1), and medium to high intensity (2). Values were not recorded when a 147 control line did not appear, when tests would subsequently be repeated ( Fig. S1A and B) . 148 Visual test interpretation was conducted independently by two separate readers and recorded 149 on data collection sheets. Readings were determined based on two of three readers' 150 interpretations. In cases where all three interpretations were different; results were registered 151 as unknown. 152 153 Each RDT's sensitivity and specificity was calculated with its respective confidence interval 155 95 (CI95) using VassarStats (http:// http://vassarstats.net/). 156 The cumulative positivity at different points of illness (from symptom appearance until day 157 31 post-appearance) was determined as follows (i) a positive result on Day N was followed by 158 subsequent positive results on Days N+1, N+2, N-n, etc and (ii) a negative result on Day N 159 was preceded by negative results on Days N-1, N-2, N-n, etc. Details of the calculation are 160 presented in Figure S2 . 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 Cumulative curves were fitted to an asymmetrical (five-parameter) logistic equation using 162 Graph Prism v6 (25). For comparative purposes, the point at which 50 cumulative positivity 163 was reached was calculated for all RDTs and expressed as the number of days post-symptom 164 onset (Fig. S3, Table 1 ). 165 The positive predictive value (PPV) and negative predictive value (NPV) were calculated as 166 follows: PPV = (sensitivity x prevalence) / [ (sensitivity x prevalence) + ((1 -specificity) x (1 167 -prevalence)) ], and NPV = (specificity x (1 -prevalence)) / [ (specificity x (1 -prevalence)) 168 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20192260 doi: medRxiv preprint Overall, 250 sera collected from 159 COVID-19 patients were selected from the BIOCOVID-187 19 Bio-bank. The median age was 62.9 years (range 12.8 -97.6) and the male/female ratio 188 was 1.69 (100/59). Among these individuals, 4.4 (7/159) were discharged after their initial 189 visit to the emergency room (ER) and 95.6 (152/159) were hospitalized. Over the study Asymmetrical (five-parameter) logistic analysis demonstrated that 50 cumulative positivity 202 (or the median time for seroconversion) varied from 7.0 to 9.6 days ( Table 1) . 203 As expected, overall test sensitivity was highest 15 days after the appearance of symptoms 204 (Table 2) , with all RDTs reaching >90 sensitivity at that point, except for RDT 6 and RDT 8 205 (81.0 and 88.5, respectively). For the 8 RDTs able to differentiate between IgM and IgG, 206 combined detection significantly increased overall test sensitivity with the exception of RDT 207 1, RDT 4 and RDT 5 (for which IgM detection seemed to be nearly as sensitive as IgM + IgG 208 detection) ( Table 2) . 209 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020. . Specificities, calculated with sera recovered from patients between 2017 and early 2019, 210 ranged from 75.7 to 99.2. Only four tests (RDT 1, RDT 4, RDT 5 and RDT 9), reached the 211 >98 threshold recommended by the French Health Authorities for serological diagnostic tests 212 (Table 2) (Table S2 ). The concordance between all tests varied from 77.0 to 96.4 except in the 219 case of the RDT 8 test that had a lower concordance with other RDTs (<80). Other RDTs 220 gave concordant results (usually ~90 to 95) (Fig. 3) . 221 The positive and negative predictive values (PPV and NPV respectively) describe the 222 performance of a diagnostic test. A high result can be interpreted as indicating the accuracy of 223 such a test. The PPV and NPV are not intrinsic to the test (as true positive rate and true 224 negative rate are) but they depend also on the prevalence. As the prevalence increases, the 225 PPV also increases but the NPV decreases. Similarly, as the prevalence decreases the PPV 226 decreases while the NPV increases. As a consequence, having both VPN and PPV above a 227 certain value can be quite challenging. Among the 10 RDTs evaluated only three presented 228 PPV and NPVs above 95 over a large window of population prevalence (RDT1, RDT 4, and 229 RDT9) (Fig. S4) . 230 231 To compare the ease of reading the RDTs' banded results, the intensity of the reaction line 233 was recorded according to 3 gradations: No signal (0), very weak but definitively positive (1), 234 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20192260 doi: medRxiv preprint and medium to high intensity (2). As shown in Figure 4 , the overall ease of reading was 235 highest for sera recovered >14-days after the appearance of symptoms. Band intensity was 236 most prominent in tests with combined antibody detection (i.e. both IgM and IgG detection; 237 RDT 9 and RDT 10 tests) (Fig. 4A) . Among the eight RDTs that differentiated between 238 antibody types, IgM band intensity was most pronounced with RDT 1 test (Fig. 4B) , with 239 RDT 3, RDT 4 and RDT 5 tests closely following. Conversely, IgM bands obtained with the 240 RDT 6, RDT 7, RDT 8 and, to a lesser extent, the RDT 2 tests were significantly less 241 pronounced (Fig.e 4B) . For IgG tests, the bands produced by the RDT 1, RDT 2, RDT 3, 242 RDT 7 and RDT 8 tests were more prominent than the RDT 4, RDT 5 and RDT 6 tests (Fig. 243 4C). 244 245 All the tests were in cassette form and nearly all devices used standard colloidal gold antigen 247 conjugated particles (Table S1 ). One test (RDT 9) used fluorescent antigen conjugated 248 particles for visualisation using a specific reader. Ease-of-use could vary from one test to 249 another, and all contained 'Instructions For User' (IFU) manuals that were in all cases 250 considered easy to understand (Table S3) (Table S3) . No users reported difficulty using the RDTs, 254 though the RDT 2 test provided a dropper with no clear instruction as to how many drops 255 should be used. Buffer for RDT 9 was included with every test tube. Less than half of the 256 RDTs (RDT 1, RDT 3, RDT 4, and RDT 5) included single-use plastic pipettes or similar 257 devices for transferring samples into the test wells. No users reported difficulties identifying 258 sample and buffer wells. All tests' results interpretation, with the exception of RDT 6, were 259 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 11, 2020. . https://doi.org/10.1101/2020.09.10.20192260 doi: medRxiv preprint considered easy. The recommended time-to-read results ranged from 10-20 minutes (Table 260 S1 ). From a packaging and legal point of view, all manufacturers except RDT 6 respected the 261 CE-IVD regulation to describe needed storage conditions in the IFU, on test packaging, and in 262 product references. RDT 6's reference test was not found on the box nor within the IFU. All 263 tests were in a single, sealed package and included a desiccant pouch. for patient management in active hospital settings and among the general public has almost 273 never been rigorously evaluated (27, 28). By demonstrating the feasibility and accuracy of 274 rapid serological immunoassays with a substantially more robust sample size than has 275 previously been described, we add depth to the evolving conversation surrounding SARS-276 CoV-2 testing strategies. We hope that knowing the analytical performance of nearly a dozen 277 commercially available tests, and by providing comparative detail, we will allow clinicians to 278 select and use these tests with more confidence and certainty. 279 This study is, to our knowledge, the first to compare diagnostic performance and time-to-280 seropositivity in nearly a dozen SAR-CoV-2 RDTs using a large sample size (250 selected 281 samples each for specificity and sensitivity, more than double other peer-reviewed, published 282 RDT evaluations). Other studies evaluating antibody tests have also not included samples 283 from patients with non-SARS-CoV-2 infections to evaluate specificity. 284 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 Overall, after the appearance of symptoms, seroconversion occurred on Days 7-9 for 50 of 285 COVID positive patients (Table 1) , with >95 seroconverting after 14 days using RDT 1, 286 RDT3, RDT 4, RDT 9 and RDT 10) and 18 days for RDT 6) (Fig. 2) . The specificities ranged 287 from 94.5-99.2, except for RDT 8 test (75.7) . Notably, the RDT 3 test produced systematic 288 false positive results with sera of patients who had a high level of rhumatoid factor (Table 289 S2). 290 Thresholds for sensitivity and specificity for RDTs have been set by many National 291 Health Authorities (21-23). For diagnosis in symptomatic patients, high sensitivity is required 292 (generally ≥ 90), while specificity is less critical as some false-positives may be tolerated as 293 other potential diagnoses are considered in parallel (RT-PCR and/or CT scans). However, if 294 LFIAs were deployed as an individual-level approach to inform release from quarantine or 295 immune-protection, then high specificity (>98) is essential, as false-positive results return 296 non-immune individuals to risk of exposure (23) Appraisal of test performance should also consider the influence of population 302 prevalence, as it may change over time, geography and within different population groups. 303 The potential risk of a test providing false positive results is crucial for release from lock-304 down of non-immune individuals. Among the 10 RDTs evaluated only three presented PPV 305 and NPVs above 95 over a large window of population prevalence (RDT1, RDT 4, and 306 RDT9). 307 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 11, 2020. . These serological tests were able to independently diagnose COVID-19, especially in 308 those with ≥ 2 weeks of symptoms, and could be used to triangulate unclear or false negative 309 results from PCR and CT testing. They could also be used to monitor the status of medical 310 and non-medical frontline workers and, over the longer term, to establish population level 311 immunity as countries' social restrictions ease. In the US (Santa Clara County, California) 312 rapid antibody tests were used to evaluate the population prevalence of antibodies (ranging 313 from 2.49-4.16) and helped authorities to understand that infection was far more widespread 314 (55-fold) than indicated by the number of confirmed cases. These data are crucial to calibrate 315 epidemic and mortality projections (29). 316 Among the three RDTs fulfilling the French health authorities' criteria, only NG-Test 317 IgG-IgM COVID-19 (NG-Biotech) might be considered a self-test since it includes all 318 materials needed for self-puncture and capillary blood recovery. Nevertheless, we only 319 authenticated this using serum, since its use has been previously established in capillary 320 whole blood and our results in serum confirm those of the initial study (30). Namely, that this 321 bedside fingerprick test confirmed infection in <15 minutes and could be performed by a 322 medical practitioner without specialized training or a pathology laboratory (30). 323 Our study is limited in the following ways: (1) RT-PCR detection was based on upper 324 respiratory tract specimens from patients with severe symptoms. None were asymptomatic 325 patients (who did not access care). (2) Most study participants' diagnoses were based on 326 positive findings from an RT-PCR test using respiratory samples. Patients with negative RT-327 PCR results but with chest imaging compatible with COVID-19 were not included. (3) 328 Because the epidemic situation in France was very recent at the time of study, samples were 329 collected during the acute phase of illness. Accordingly, we do not yet have sera from later 330 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020. . stages to evaluate antibody persistence. (4) Only 10 out of more than 170 available RDTs 331 have been evaluated. 332 The COVID-19 pandemic has revealed gaps in our diagnostic arsenal and is highlighting the 333 essential role of serodiagnostics in public health response (31). With the use of carefully 334 verified assays, appropriately designed serologic studies will help characterize transmission 335 dynamics, refine disease burden estimates, diagnose suspected cases, and confirm clinically 336 diagnosed patients without access to Though this assessment demonstrates varied analytical performance across a sample of 338 current SARS-CoV-2 RDTs, they nevertheless hold real utility as tool for establishing 339 population level exposure: many people have been exposed more than 3 weeks prior to 340 antibody testing and would benefit from the nearly 100 sensitivity (in all tests evaluated) after 341 3 weeks' time. However, highly sensitive (as early as 7 days) and specific tests are needed, 342 both to achieve sufficiently high positive predictive values since population prevalence is 343 often estimated to be low (≤5), and to be clinically useful as an initial diagnostic assay and a 344 complement to direct RNA testing. Only three of the evaluated assays met the thresholds 345 needed (sensitivity of >90 at 14 days after symptom appearance and >98 specificity). 346 Serological assays are simple, cheap, rapid, easy to interpret, and practical (can be stored at 347 room temperature). They detect IgM, IgG, or both and can be performed directly at a patient's 348 bedside, at a general physician's office, or when triaging in an emergency department, as 349 most have been validated using whole blood. 350 The authors declare no conflict of interest 353 354 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020. . This research was supported by Assistance Publique -Hôpitaux de Paris (APHP), Médecins 356 Sans Frontières (MSF), and by a Grant from the French Defence Innovation Agency (AID). 357 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 11, 2020. . . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Substantial 359 undocumented infection facilitates the rapid dissemination of novel coronavirus 360 (SARS-CoV-2) Presumed 362 asymptomatic carrier transmission of COVID-19 Estimating the 365 asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the 366 Diamond Princess cruise ship Potential presymptomatic transmission of SARS-CoV-2 Modelling COVID-19 transmission: from data to intervention Social distancing to combat COVID-373 19: We are all on the front line Detection of 378 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Laboratory Diagnosis of 380 COVID-19: Current Issues and Challenges COVID-19) in suspected human cases Time kinetics of viral clearance and resolution of symptoms in 388 novel coronavirus infection CoV-2 in different types of clinical specimens Molecular and serological investigation of 2019-nCoV 393 infected patients: implication of multiple shedding routes The role of chest imaging in patient 400 management during the COVID-19 pandemic: A multinational consensus statement 401 from the Fleischner society 403 Diagnostic value and dynamic variance of serum antibody in coronavirus disease 404 2019 Virological assessment of hospitalized patients with COVID-2019 Immunological assays for SARS-CoV-2: an 417 analysis of available commercialtests to measure antigen and antibodies Evaluation of nine commercial SARS-CoV-2 immunoassays Test performance evaluation of SARS-CoV-2 serological 433 assays Food and Drug Administration. 2020. Policy for coronavirus disease-2019 tests during 445 the public health emergency (revised Cahier des charges définissant les modalités 447 d'évaluation des performances des tests sérologiques détectant les anticorps dirigés 448 contre le SARS-CoV-2 STARD 2015 guidelines for 452 reporting diagnostic accuracy studies: explanation and elaboration Assessing the (a)symmetry of 455 concentration-effect curves: empirical versus mechanistic models Studies on the generality of affective meaning systems Detection of SARS-CoV-2 antibodies using commercial assays and 462 seroconversion patterns in hospitalized patients Diagnostic performance of seven rapid 465 IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients COVID-19 antibody 470 seroprevalence in Rapid determination of SARS-CoV-2 474 antibodies using a bedside, point-of-care Serodiagnostics for severe acute respiratory syndrome-related coronavirus-2: 479 A narrative review